SGS leadership in April was invited by ACOG and agreed to sign on to the Amicus Brief in the Louisiana v FDA (SCOTUS) case. This case concerns FDA regulations that allow clinicians to prescribe, and patients to access, one of the two drugs used in the standard protocol for medication abortion and miscarriage management, known in its generic form as mifepristone. Specifically, the brief asks the Court to vacate or stay the Fifth Circuit’s order staying the 2023 REMS under 5 U.S.C. § 705 and reinstating a nationwide requirement that mifepristone be dispensed only at a hospital, clinic, or medical office rather than by mail or at a pharmacy. The brief references overwhelming data supporting the safety of mifepristone whether dispensed in person or not.
SGS joins ACOG and 19 other medical societies in filing this brief, representing hundreds of thousands of obstetricians and gynecologists. For more than two decades, mifepristone has undergone rigorous scientific testing and has been found safe and effective when used for abortion care and miscarriage management, regardless of whether it is dispensed in person.
We remain committed to advancing evidence-based policies that protect patient access to care.
Read the full brief here.